Do NAD+ and Peptides Actually Extend Lifespan?

The short answer

NAD+ precursors (NMN and NR) do one thing reliably in humans: they raise blood NAD+. Whether that translates into a longer or healthier life is unproven. Peptide and growth-hormone protocols sold alongside them carry real cautions and even thinner evidence. This is the honest version of a story the supplement industry tends to oversell. For the full toolkit, see our pillar on longevity medicine: what's proven vs hyped.

NAD+ precursors: target engagement is real

The strongest claim you can honestly make about NMN and NR is that they hit their biochemical target. A placebo-controlled crossover trial showed oral nicotinamide riboside (1000 mg/day) is well tolerated and roughly doubles blood NAD+ in healthy middle-aged and older adults¹. That is genuine target engagement — the supplement does what it says at the molecular level.

The problem is what happens next. In that same trial, the signal on blood pressure and arterial stiffness was only suggestive, not statistically significant¹. Raising NAD+ is not the same as improving health.

The human outcome data is modest and mixed

There are real positive signals, and we won't bury them. A randomized, placebo-controlled trial found that 10 weeks of NMN (250 mg/day) improved skeletal-muscle insulin sensitivity in prediabetic postmenopausal women². A small double-blind trial reported NMN improved aerobic capacity in amateur runners, though the effect was partly attributed to training-driven oxygen utilization³.

Against those sit two sobering data points. A physiologic study in overweight and older adults confirmed NR raised whole-blood NAD+ but found no significant improvement in muscle function, aerobic capacity, mitochondrial function, or metabolic parameters⁴. And a systematic review and meta-analysis concluded that NAD+ precursor supplementation does not produce consistent, clinically meaningful improvements in metabolic-syndrome parameters⁵. For the full trial-by-trial breakdown — including the Parkinson's and heart-failure studies and why the Sinclair-adjacent hype outran the data — see NAD+ for longevity: what the trials actually show.

The honest read: narrow surrogate wins in specific populations, no consistent benefit overall, and zero lifespan or healthspan hard-outcome data. NAD+ precursors are plausible, well tolerated, and unproven for longevity. The one mitochondrial supplement with a cleaner functional-trial record is urolithin A — see urolithin A (Mitopure): mitochondrial hype or real? for the rare case where multiple RCTs show modest muscle gains, though still no lifespan data.

Why "NAD+ went up" isn't the win it sounds like

The most common sales pitch for NAD+ supplements is that NAD+ declines with age and these compounds restore it. The decline is real, and these compounds do raise NAD+. But the logic skips a step: it assumes that restoring a biomarker restores the health that biomarker is associated with. The physiologic study is the clearest counterexample — NAD+ rose, and nothing functional improved⁴. Biomarkers can be markers of aging without being levers that, when pushed, reverse it. Until trials show that raising NAD+ changes outcomes you can feel — strength, endurance, metabolic health, or hard events — "your NAD+ went up" is a chemistry result, not a health result.

Peptides and growth hormone: caution, not magic

"Peptide therapy" at longevity clinics often means growth-hormone secretagogues — compounds meant to push your body to make more growth hormone. The marketing frames this as rejuvenation. The evidence frames it as risk.

A landmark systematic review found that in healthy older adults, growth hormone produced small body-composition changes but no proven functional benefit, alongside significantly more adverse events: edema, joint pain, gynecomastia, and glucose intolerance⁶. The direction of the underlying biology is even more striking — across species, reduced GH/IGF-1 signaling is associated with extended lifespan, directly contradicting the idea that more growth hormone makes you younger⁷.

If raising GH/IGF-1 were a longevity strategy, the animal data would point that way. It points the opposite way. That is why we grade GH and GH-secretagogue "peptides" as cautioned against, not promising. Many other "peptides" marketed for recovery, sleep, or vague optimization simply lack any human longevity evidence at all — they are sold on mechanism and anecdote. Absence of trials is not the same as evidence of benefit, and a peptide stack with no published human outcome data should be treated as experimental, not as a longevity protocol. For the full category-by-category breakdown — secretagogues like MK-677, GHRH analogs like tesamorelin, and "healing" peptides like BPC-157 and GHK-Cu — see our dedicated review of peptides for longevity: what's real and what's marketing.

What this means for you

• •NAD+ (NMN/NR): reliably raises NAD+, generally well tolerated, but human outcomes are modest and mixed. Reasonable to be curious about; not proven to extend life.
• •GH / GH-secretagogue peptides: no proven functional benefit in healthy adults, more side effects, and biology that runs against the longevity claim. Approach with skepticism.
• •Watch the endpoint switch: when a clinic cites "NAD+ went up" or "IGF-1 increased," ask whether any outcome you care about changed. Usually it hasn't been measured.

For how these intervention claims play out at commercial clinics, see are longevity clinics worth it? — and for the drugs with the most animal data, rapamycin & metformin for longevity.